SYBLEU (SYBE) 10-Q/A 16 Mar 22 2021 Q3 Quarterly report (amended) Financial data

Cover

Cover - shares	9 Months Ended
	Mar. 31, 2021	Sep. 20, 2021
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	EXPLANATORY NOTE: THIS AMENDMENT NO.1 TO SYBLEU INC’S (THE “COMPANY”) FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2021 (“ORIGINAL FILING”) IS BEING FILED SOLELY TO AMEND THE FOLLOWING PORTIONS OF THE ORIGINAL FILING.
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--06-30
Entity File Number	333-248059
Entity Registrant Name	SYBLEU Inc
Entity Central Index Key	0001818674
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	St 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	WY
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,418,000

CONDENSED BALANCE SHEETS (Unaud

CONDENSED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
CURRENT ASSETS
Cash	$ 27,002	$ 5,050
Prepaid Expenses	0	3,500
Total Current Assets	27,002	8,550
OTHER ASSETS
Investment Securities	133,900
Total Other Assets	133,900
TOTAL ASSETS	160,902	8,550
Current Liabilities:
Income Taxes Payable	21,394
Notes Payable, Related Party	8,919	11,329
Expenses Accrued but Unpaid	0	0
Total Current Liabilities	30,313	11,329
Long Term Liabilities:
Unearned Income	176,315
Total Liabilities	206,628	11,329
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value) 100,000,000 shares authorized; par value $0.00019,353,000 shares issued and outstanding as of June 30,2020 and 10,418,000 shares issued and outstanding as of March 31,2021	1,042	935
Additional Paid in capital	100,049	145
Retained Deficit	(146,817)	(3,859)
Total Stockholders' Equity (Deficit)	(45,726)	(2,779)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 160,902	$ 8,550

CONDENSED BALANCE SHEETS (Una_2

CONDENSED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2021	Jun. 30, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,418,000	9,353,000
Common stock, shares outstanding	10,418,000	9,353,000

CONDENSED STATEMENT OF OPERATIO

CONDENSED STATEMENT OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2021
REVENUES
License Fees	$ 1,135	$ 1,135
TOTAL REVENUES	1,135	1,135
Research and Development:
Consulting Costs	11,350	23,161
Patent Application Costs		3,100
Total Research and Development	11,350	26,261
General and Administrative:
Transfer Agency Fees	150	5,365
Other General and Administrative Expenses	750	1,643
Total General and Administrative	900	7,008
Legal Fees		500
Accounting	3,240	11,880
Other Consulting		13,600
Information Technology Consulting	7,300	19,900
Total Consulting	10,540	45,880
Total Costs and Expenses	22,790	79,149
OPERATING Income (LOSS)	(21,655)	(78,014)
OTHER INCOME AND EXPENSES
Unrealized Gain ( Loss) on Investment Securities	(43,550)	(43,550)
TOTAL OTHER INCOME ( EXPENSES)	(43,550)	(43,550)
NET LOSS Before taxes	(65,205)	(121,564)
Provision for Income Taxes	(21,394)	(21,394)
NET INCOME ( LOSS)	$ (86,599)	$ (142,958)
BASIC AND FULLY DILUTED LOSS PER SHARE	$ (0.01)	$ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	10,418,000	9,970,740

CONDENSED STATEMENT OF SHAREHOL

CONDENSED STATEMENT OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock	Additional Paid-In Capital	Retained Deficit	Total
Beginning balance, value at Jun. 30, 2020	$ 935	$ 145	$ (3,859)	$ (2,779)
Balance at beginning, share at Jun. 30, 2020	9,353,000
Common shares issued for nonemployee services July 8,2020, value	$ 7	4		11
Common shares issued for nonemployee services July 8,2020, shares	65,000
Net Loss			(21,896)	(21,896)
Ending balance, value at Sep. 30, 2020	$ 942	149	(25,755)	(24,664)
Ending at balance, shares at Sep. 30, 2020	9,418,000
Common Shares issued for cash November 9,2020, value	$ 100	99,900		100,000
Common Shares issued for cash November 9,2020, shares	1,000,000
Net Loss			(34,463)	(34,463)
Ending balance, value at Dec. 31, 2020	$ 1,042	100,049	(60,218)	40,873
Ending at balance, shares at Dec. 31, 2020	10,418,000
Net Loss			(86,599)	(86,599)
Ending balance, value at Mar. 31, 2021	$ 1,042	$ 100,049	$ (146,817)	$ (45,726)
Ending at balance, shares at Mar. 31, 2021	10,418,000

CONDENSED STATEMENT OF CASH FLO

CONDENSED STATEMENT OF CASH FLOWS (Unaudited)	9 Months Ended
	Mar. 31, 2021USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ (142,958)
Adjustments to reconcile net Income (loss) to net cash
Common Stock Issued for payment of expenses	11
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses	3,500
Increase (Decrease) in Accrued Expenses	0
(Increase) Decrease in Securities accepted as Payment	(177,450)
Increase ( Decrease) in Unearned Income	176,315
Increase (Decrease) in Income Tax Payable	21,394
Unrealized Loss ( Gain) in Investment Securities	43,550
Net Cash provided by (used) in Operating Activities	(75,638)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase ( Decrease) in Notes Payable, Related Parties	(2,410)
Common Stock issued for Cash	100,000
Net Cash provided by (used) in Financing Activities	97,590
Net Increase (Decrease) in Cash	21,952
Cash at Beginning of Period	5,050
Cash at End of Period	27,002
Supplemental Cash Flow Information:
Interest Paid	0
Income Taxes Paid	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SYBLEU INC. (“Company”) was organized June 12, 2020 under the laws of the State of Wyoming. The Company intends to engage primarily in the development of regenerative medical applications up to the point of successful completion of Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The primary factor to be considered by us in arriving at a decision to advance an application further to Phase III clinical trials would be a greater than anticipated indication of efficacy seen in Phase I trials. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end. B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application. Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the quarter ended March 31 ,2021 no stock was issued for employee compensation. Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees. In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant. Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. During the quarter ended March 31,2021, no stock was issued for non- employee compensation. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of March 31, 2021.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS The Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. The Company has adopted the provisions of this ASU effective the fiscal year ended 2020. This guidance did not have a material impact on the Company’s Financial Statements. On February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The ASU requires organizations that lease assets, referred to as “lessees,” to recognize on the consolidated statement of financial position the rights and obligations created by those leases. The ASU also requires disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative requirements, providing additional information about the amounts recorded in the consolidated financial statements. The ASU on leases became effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company has not adopted the provisions of this ASU. This guidance is not expected to have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has generated net losses of $146,817 during the period from June 12, 2020 (inception) through March 31,2021. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. On November 5th, 2020 the Company sold one million of its common shares (“Shares”) to The Stephen and Fredna Hake Trust DTD August 6, 2014 for consideration of $100,000. Dr. Stephen Hake, a Trustee of the Stephen and Fredna Hake Trust DTD August 6, 2014, serves as a member of the Scientific Advisory Board of the Company and has a pre-established relationship with the Company.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4. RELATED PARTY TRANSACTIONS. As of March 31, 2021 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $1,879 ( “Koos Notes”). As of March 31,2021 the Company is indebted to BST Partners, Inc. , a company controlled by David Koos, in the amount of $7,040 ( “BST Notes”) Both the Koos Notes and BST Notes bear no interest and are due and payable upon demand of the Holder. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 provided to the Company by BST Partners, Inc. on a month to month basis free of charge. The property is utilized as office space. We believe that the foregoing properties are adequate to meet our current needs for office space.

NOTES PAYABLE RELATED PARTY

NOTES PAYABLE RELATED PARTY	9 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE RELATED PARTY	NOTE 5. NOTES PAYABLE RELATED PARTY David Koos 1,879 BST Partners 7,040 Notes Payable, Related Parties $ 8,919 As of March 31, 2021 the Company is indebted to David R. Koos in the amount of $1,879. As of March 31, 2021 the Company is indebted to BST Partners in the amount of $7,040. BST Partners is controlled by David R. Koos.

INVESTMENT SECURITIES

INVESTMENT SECURITIES	9 Months Ended
	Mar. 31, 2021
Schedule of Investments [Abstract]
INVESTMENT SECURITIES	NOTE 6. INVESTMENT SECURITIES On March 11, 2021 the Company was paid 6,500 common shares of Oncology Pharma, Inc. pursuant to an agreement entered into by and between the Company and Oncology Pharma, Inc. whereby the Company granted Oncology Pharma, Inc. an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by the Company. On March 31, 2021 the Company revalued 6,500 common shares of Oncology Pharma, Inc. at the closing price of the common shares on the OTC Pink market. As of March 31, 2021: 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the Quarter ended March 31,2021 $ 177,450 $ 133,900 $ 43,550 $ (43,550)

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Mar. 31, 2021
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 7. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following class of capital stock as of March 31, 2021: Common stock, $ 0.0001 par value; 100,000,000 shares authorized: 10,418,000 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

STOCK TRANSACTIONS

STOCK TRANSACTIONS	9 Months Ended
	Mar. 31, 2021
Equity [Abstract]
STOCK TRANSACTIONS	NOTE 9. STOCK TRANSACTIONS No equity securities were issued by the Company during the quarter ended March 31,2021.

RESTATEMENT OF PREVIOUSLY ISSUE

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	9 Months Ended
	Mar. 31, 2021
Restatement Of Previously Issued Financial Statements
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS	NOTE 10. RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS Subsequent to the original issuance of the Company’s quarterly financial statements for the period ended March 31, 2021 the Company determined that the following revisions are required Recognizing revenue of $177,450 resulting from licensing fees paid during the quarter ended March 31,2021 over the term of the license ( 15 years) Cumulative Effect of Restatement of Previously Issued Financial Statements for the Quarter Ended March 31, 2021. Quarter Ended March 31, 2021 Condensed Balance Sheet As Originally Presented Adjustments As Restated Unearned Income 0 176,315 176,315 Total Liabilities: 30,313 176,315 206,628 Retained Earnings (Deficit ) 29,498 (176,315 ) (146,817 ) Total Stockholders’ Equity (Deficit) 130,589 (176,315 ) (45,726 ) Quarter Ended March 31, 2021 Condensed Statement of Operations As Originally Presented Adjustments As Restated License Fees 177,450 (176,315 ) 1,135 Total Revenue 177,450 (176,315 ) 1,135 Operating Income ( Loss) 154,660 (176,315 ) (21,655 ) Net Income ( Loss) Before Taxes 111,110 (176,315 ) (65,205 ) Net Income (Loss ) 89,716 (176,315 ) (86,599 ) Nine Months Ended March 31, 2021 Condensed Statement of Operations As Originally Presented Adjustments As Restated License Fees 177,450 (176,315 ) 1,135 Total Revenue 177,450 (176,315 ) 1,135 Operating Income ( Loss) 98,301 (176,315 ) (78,014 ) Net Income (Loss) Before Taxes 54,751 (176,315 ) (121,564 ) Net Income (Loss ) 33,357 (176,315 ) (142,958 ) Nine Months Ended March 31, 2021 Condensed Statement of Shareholders’ Equity As Originally Presented Adjustments As Restated Net Income ( Loss) Quarter ended March 31, 2021 89,716 (176,315 ) (86,599 ) Retained Deficit March 31, 2021 29,498 (176,315 ) (146,817 ) Total Stockholders’ Equity (Deficit) March 31, 2021 130,589 (176,315 ) (45,726 )) Nine Months Ended March 31, 2021 Condensed Statement of Cash Flows As Originally Presented Adjustments As Restated Net Income (Loss) 33,357 (176,315 ) (142,958 ) Increase ( Decrease) in Unearned Income 0 176,315 176,315

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a June 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
FAIR VALUE OF FINANCIAL INSTRUMENTS	D. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
RESEARCH AND DEVELOPMENT COSTS	E. RESEARCH AND DEVELOPMENT COSTS Research and development expenses relate primarily to the cost of discovery and research programs. Research and development costs are charged to expense as incurred. Research and development expenses consist mainly of evaluating potential Contract Research Organizations and filing of a provisional patent application.
STOCK BASED COMPENSATION	F. STOCK BASED COMPENSATION Stock issued for Employee Compensation Stock based compensation to employees is accounted for at the award’s fair value at grant, less the amount (if any) paid by the award recipient. During the quarter ended March 31 ,2021 no stock was issued for employee compensation. Stock issued for Non-Employee Services Stock Based compensation to non-employees is accounted for in accordance with ASC 505-50. ASC 505-50 requires entities to account for non-employee equity transactions based on either the fair value of the services received or the fair value of the equity instrument issued utilizing whichever measurement is most reliable. Stock issued for compensation to non employees during the quarter ended September 30, 2020 was accounted for at the fair value of the equity instruments issued as there were no dollar amounts billed to the Company for services rendered by the non employees. In determining the Fair Value of shares issued as compensation, the Company took into account factors including the financial condition of the Company at the time of grant, the Company’s lack of profitability, the lack of cash sales of the Company’s stock, and the Company’s negative working capital as of the time of grant. Pursuant to ASC 505-50-30-11505-50-30-11 an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date: i. The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and ii. The date at which the counterparty’s performance is complete. During the quarter ended March 31,2021, no stock was issued for non- employee compensation.
INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of March 31, 2021 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	H. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. There were no Common Stock Equivalents as of March 31, 2021.

NOTES PAYABLE RELATED PARTY (Ta

NOTES PAYABLE RELATED PARTY (Tables)	9 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Schedule of related party debt	David Koos 1,879 BST Partners 7,040 Notes Payable, Related Parties $ 8,919

INVESTMENT SECURITIES (Tables)

INVESTMENT SECURITIES (Tables)	9 Months Ended
	Mar. 31, 2021
Schedule of Investments [Abstract]
Comprehensive Income	As of March 31, 2021: 6,500 Common Shares of Oncology Pharma, Inc. Basis Fair Value Total Unrealized Losses Net Unrealized Gain or (Loss) realized during the Quarter ended March 31,2021 $ 177,450 $ 133,900 $ 43,550 $ (43,550)

RESTATEMENT OF PREVIOUSLY ISS_2

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEM ENTS (Tables)	9 Months Ended
	Mar. 31, 2021
Restatement Of Previously Issued Financial Statements
Schedule of restatement of previously issued Financial Statements	Cumulative Effect of Restatement of Previously Issued Financial Statements for the Quarter Ended March 31, 2021. Quarter Ended March 31, 2021 Condensed Balance Sheet As Originally Presented Adjustments As Restated Unearned Income 0 176,315 176,315 Total Liabilities: 30,313 176,315 206,628 Retained Earnings (Deficit ) 29,498 (176,315 ) (146,817 ) Total Stockholders’ Equity (Deficit) 130,589 (176,315 ) (45,726 ) Quarter Ended March 31, 2021 Condensed Statement of Operations As Originally Presented Adjustments As Restated License Fees 177,450 (176,315 ) 1,135 Total Revenue 177,450 (176,315 ) 1,135 Operating Income ( Loss) 154,660 (176,315 ) (21,655 ) Net Income ( Loss) Before Taxes 111,110 (176,315 ) (65,205 ) Net Income (Loss ) 89,716 (176,315 ) (86,599 ) Nine Months Ended March 31, 2021 Condensed Statement of Operations As Originally Presented Adjustments As Restated License Fees 177,450 (176,315 ) 1,135 Total Revenue 177,450 (176,315 ) 1,135 Operating Income ( Loss) 98,301 (176,315 ) (78,014 ) Net Income (Loss) Before Taxes 54,751 (176,315 ) (121,564 ) Net Income (Loss ) 33,357 (176,315 ) (142,958 ) Nine Months Ended March 31, 2021 Condensed Statement of Shareholders’ Equity As Originally Presented Adjustments As Restated Net Income ( Loss) Quarter ended March 31, 2021 89,716 (176,315 ) (86,599 ) Retained Deficit March 31, 2021 29,498 (176,315 ) (146,817 ) Total Stockholders’ Equity (Deficit) March 31, 2021 130,589 (176,315 ) (45,726 )) Nine Months Ended March 31, 2021 Condensed Statement of Cash Flows As Originally Presented Adjustments As Restated Net Income (Loss) 33,357 (176,315 ) (142,958 ) Increase ( Decrease) in Unearned Income 0 176,315 176,315

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	9 Months Ended
	Mar. 31, 2021USD ($)shares
Accounting Policies [Abstract]
Uncertain tax positions | $	$ 0
Anti-dilutive securities | shares	0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Nov. 05, 2020	Mar. 31, 2021
Net losses		$ 146,817
Stephen Hake
Proceeds from sale of common stock	$ 100,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	9 Months Ended
	Mar. 31, 2021USD ($)
BST Partners [Member]
Proceeds from related debt	$ 7,040
David R. Koos [Member]
Proceeds from related debt	$ 1,879

NOTES PAYABLE RELATED PARTY (De

NOTES PAYABLE RELATED PARTY (Details)	Mar. 31, 2021USD ($)
Notes Payable, Related Parties	$ 8,919
David R. Koos [Member]
Notes Payable, Related Parties	1,879
BST Partners [Member]
Notes Payable, Related Parties	$ 7,040

NOTES PAYABLE RELATED PARTY (_2

NOTES PAYABLE RELATED PARTY (Details Narrative)	Mar. 31, 2021USD ($)
Notes Payable, Related Parties	$ 8,919
David R. Koos [Member]
Notes Payable, Related Parties	1,879
BST Partners [Member]
Notes Payable, Related Parties	$ 7,040

INVESTMENT SECURITIES (Details)

INVESTMENT SECURITIES (Details) - Oncology Pharma, Inc [Member]	9 Months Ended
	Mar. 31, 2021USD ($)
Investment Securities, Basis	$ 177,450
Investment Securities, Fair Value	133,900
Investment Securities, Total Unrealized Losses	43,550
Investment Securities, Net Unrealized Gain or (Loss) realized	$ (43,550)

INVESTMENT SECURITIES (Details

INVESTMENT SECURITIES (Details Narrative)	9 Months Ended
	Mar. 31, 2021shares
Oncology Pharma, Inc [Member]
Number of shares issued for property dividend	6,500

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - $ / shares	Mar. 31, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Common Stock par value	$ 0.0001	$ 0.0001
Common Stock shares authorized	100,000,000	100,000,000
Common Stock shares issued	10,418,000	9,353,000
Common Stock shares outstanding	10,418,000	9,353,000

RESTATEMENT OF PREVIOUSLY ISS_3

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2021	Jun. 30, 2020
Unearned Income	$ 176,315	$ 176,315
Total Liabilities:	206,628	206,628	$ 11,329
License Fees	1,135	1,135
Total Revenue	1,135	1,135
Operating Income ( Loss)	(21,655)	(78,014)
Increase ( Decrease) in Unearned Income		176,315
As Originally Presented [Member]
Unearned Income	0	0
Total Liabilities:	30,313	30,313
Retained Earnings (Deficit )	29,498	29,498
Total Stockholders' Equity (Deficit)	130,589	130,589
License Fees	177,450	177,450
Total Revenue	177,450	177,450
Operating Income ( Loss)	154,660	98,301
Net Income ( Loss) Before Taxes	111,110	54,751
Net Income (Loss )	89,716	33,357
Increase ( Decrease) in Unearned Income		0
Revision of Prior Period, Adjustment [Member]
Unearned Income	176,315	176,315
Total Liabilities:	176,315	176,315
Retained Earnings (Deficit )	(176,315)	(176,315)
Total Stockholders' Equity (Deficit)	(176,315)	(176,315)
License Fees	(176,315)	(176,315)
Total Revenue	(176,315)	(176,315)
Operating Income ( Loss)	(176,315)	(176,315)
Net Income ( Loss) Before Taxes	(176,315)	(176,315)
Net Income (Loss )	(176,315)	(176,315)
Increase ( Decrease) in Unearned Income		176,315
As Restated [Member]
Unearned Income	176,315	176,315
Total Liabilities:	206,628	206,628
Retained Earnings (Deficit )	(146,817)	(146,817)
Total Stockholders' Equity (Deficit)	(45,726)	(45,726)
License Fees	1,135	1,135
Total Revenue	1,135	1,135
Operating Income ( Loss)	(21,655)	(78,014)
Net Income ( Loss) Before Taxes	(65,205)	(121,564)
Net Income (Loss )	$ (86,599)	(142,958)
Increase ( Decrease) in Unearned Income		$ 176,315

RESTATEMENT OF PREVIOUSLY ISS_4

RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Details Narrative)	3 Months Ended
	Mar. 31, 2021USD ($)
Disclosure Restatement Of Previously Issued Financial Statements Abstract
Licensing fees paid	$ 177,450
License term	15 years